Clinical trial
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
NCT03019666 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT03019666 |
|---|---|
| Title | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
| Official title | A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma |
| Intervention type | Biological |
| Interventions | Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells |
| Enrollment | 39 |
| Start date | Oct 18, 2017 |
| Primary completion | Aug 15, 2022 |
| Completion | Aug 15, 2022 |
| First posted | Jan 12, 2017 |
| Last update posted | Nov 4, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: